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To verify the susceptibility of ventricle to arrhythmia after bone marrow mononuclear cell
transplantation (BMMNCT), we measured ventricular ﬁbrillation threshold (VFT) and
monophasic action potential duration (MAPD90). Lewis rats with doxorubicin-induced
cardiomyopathy were divided into 2 groups: transplantation group (D–TX: BMMNC (1
106) given transplants into the apex at 4 weeks after doxorubicin administration) and non-
transplantation group (D–N). Age-matched normal group (N–N) was prepared. At 4 weeks
after BMMNCT, the following electrophysiologic tests were performed. Experiment 1 (VFT):
Two stainless wires were placed at the apex and a single train of 10 square wave stimuli was
delivered across T wave. The lowest current developing ventricular ﬁbrillation was
determined as VFT. Experiment 2 (MAPD90): The catheter was inserted into the left
ventricle and pressed against the endocardium near the apex under regular cycle lengths.
Experiment 1: VFT of D–TX and D–N were signiﬁcantly lower than that of N–N (p < 0:01).
There was no diﬀerence between D–TX and D–N. Experiment 2: MAPD90 of each group was
lined up in length D–N > D–TX > N–N at every cycle lengths. There was a signiﬁcant
diﬀerence between D–N and N–N (p < 0:01), and D–TX and N–N (p < 0:05). In this model,
BMMNCT did not increase susceptibility to arrthythmia.
(J Arrhythmia 2006; 22: 86–91)
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Introduction
Numerous animal studies have shown evidence
that cell transplantation improves cardiac func-
tion.1–4) These studies reported that arrhythmia was
not detected after cell transplantation by conven-
Address for correspondence: Masaki Hamamoto MD, Department of Cardiovascular Surgery, Onomichi General Hospital Kohama 7-19,
Onomichi, Hiroshima, Postal code 722-8508. TEL: 0848-22-8111 FAX: 0848-23-3214 E-mail: hamamotomasaki@hotmail.com
Received 1, February, 2006: accepted in ﬁnal form 21, April, 2006.
86
J Arrhythmia Vol 22 No 2 2006
Original Article
tional methods such as electrocardiographic mon-
itorings.5) Based on these previous studies, clinical
trials for ischemic heart disease were started.
Menasche´ et al. ﬁrst demonstrated that autologous
skeletal myoblasts transplanted into the infarcted
heart revived cardiac contractility in a phase I
clinical trial.6) However, they also gave warning
regarding arrhythmia possibly related to cell trans-
plantation. In their report, four out of ten patients had
episodes of ventricular tachycardia and cardioverter
deﬁbrillators were implanted.7) In another clinical
trial, Smits et al. demonstrated that 4 of 13 patients
experienced ventricular tachycardia after catheter-
based endocardial transplantation of autologous
skeletal myoblasts for the ischemic heart failure,
and half of them needed ICD implantation.8) In
contrast, there are several on-going clinical trials for
myocardial infarction using bone marrow cells and
they have showed no critical arrhythmia so far.9,10)
Considering the results of these clinical trials and
safety for further trials, it is deﬁnitely important
to investigate the issue of arrhythmia after the cell
transplantation using diﬀerent methodologies. In our
previous study, we have reported that bone marrow
mononuclear cell transplantation had favorable
eﬀects in a rat doxorubicin-induced cardiomyopathy
model in terms of systolic cardiac function, the
concentration of atrial natriuretic peptide, and myo-
cardial ultrastructures evaluated by electron and light
microscopic study.4) On the basis of this experiment,
we next focused on one of the very important issues
of arrhythmia related to cell transplantation using the
same animal model. To clarify this issue, we
evaluated ventricular ﬁbrillation thresholds (VFT)
using the train-stimuli technique11,12) and action
potential duration (APD) using monophasic action
potential (MAP) recording,13) both of which are
conventional methods in electrophysiology, after
bone marrow cell transplantation for a rat doxor-
ubicin-induced cardiomyopathy model,4) and veri-
ﬁed whether bone marrow transplantation would
suppress arrhythmogenicity of the diseased heart.
Methods
Animal preparation
Animals were studied based on guidelines pub-
lished in the National Institutes of Health Guide for
the Care and Use of laboratory Animals (NIH
publication 85-23, revised 1985) and approved by
the Institutional Animal Care and Use Committee at
National Cardiovascular Center Research Institute,
Osaka, Japan. Adult male Lewis rats (9-week-old,
230–270 g) were purchased from a licensed vendor
and were housed in an air-conditioned room with
free access to food and water at all time.
Generation of Doxorubicin-induced cardiomyo-
pathy
Doxorubicin-induced cardiomyopathy was gener-
ated as described by our previous study.4) In brief,
doxorubicin hydrochloride (Sigma Chemical Co., St.
Louis, USA) (2.5mg/kg  6 within 2 weeks) was
intraperitoneally administrated to the rats. They were
randomly divided into two groups: Cell transplanta-
tion group (D–TX) and non-cell transplantation
group (D–N). Normal rat group in the same age
was also prepared without doxorubicin administra-
tion and cell transplantation (N–N). Experimental
protocol was shown in Figure 1.
Preparation and transplantation of bone marrow
mononuclear cells (BMMNC)
At 4 weeks after the ﬁnal administration of
doxorubicin hydrochloride, bone marrow cell trans-
plantation into the heart was performed for rats in D–
TX.4) We prepared BMMNC from other syngenic
normal rats just prior to the cell transplantation. The
rats were anesthetized with an intramuscular admin-
istration of ketamine hydrochloride (3mg), and an
intraperitoneal injection of sodium pentobarbital
(10mg) and heparin (100 units). Both legs were
cut and bone marrow was extracted with a 22-gauge
needle. The bone marrow cells were transferred to
a sterile tube containing phosphate buﬀered saline
(PBS). The cell suspension was loaded on Percoll
gradient (Lymphoprep, Amersham Biosciences
Corp., Piscataway, USA). The cells were centrifuged
at 800 g for 20 minutes at 4 C. The top two thirds of
the total volume were transferred into a tube then
washed with PBS to remove the Percoll. The cell
pellet was resuspended with PBS to obtain a
concentration of 1 106 cells in 40 ml. Subsequently
Doxorubicin
(2.5 mg/kg × 6 times)
0 2 6 10 weeks
BMMNC
Transplantation
(1x106/40μl) 
Measurement
of
VFT and APD
N-N    (n=10 for VFT and n= 5 for MAPD)
D-TX  (n=10 for VFT and n= 5 for MAPD)
D-N    (n=10 for VFT and n= 5 for MAPD)
Figure 1 Experimental protocol.
BMMNC, bone marrow mononuclear cell; VFT, ventricular
ﬁbrillation threshold; APD, action potential duration; N–N,
normal group; D–N, non-transplantation group; D–TX, trans-
plantation group.
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the rats with doxorubicin-induced cardiomyopathic
heart were anesthetized by the same method as
mentioned above. They were intubated and venti-
lated using ventilator (Shimano Medical, Matsu-
moto, Japan) under the setting of the respiratory rate
of 70 /minute, tidal volume of 8ml/kg, and room
air supplemented with 2 L/minute of oxygen. The
heart was exposed through lateral thoracotomy.
Prepared BMMNC (1 106 cells/40 ml) were in-
jected at the apex toward the left ventricular free
wall with a 31-gauge tuberculin syringe. To prevent
leakage, the injection site was purse-string sutured
with 6-0 polypropylene. The chest was closed with
3-0 polypropylene in three layers. We did not
perform any surgical procedures for the rats in
D–N and N–N.
Electrophysiologic testing
At 4 weeks after the cell transplantation, cardiac
electrophisiologic testing was performed for all
groups. The rats were anesthetized by intraperitoneal
administration of sodium pentobarbital (125mg/kg),
and ventilated as mentioned above. Three 27-gauge
needles were subcutaneously placed for ECG record-
ing, and a 24-gauge catheter was inserted into the
left femoral artery for monitoring arterial pressure.
The heart was exposed through median sternotomy.
Measurement of VFT12) (n ¼ 10 for each group)
We measured VFT as an index of vulnerability to
ventricular ﬁbrillation (VF), using the train-stimuli
method. A pair of polyurethane-coated stainless steel
wire electrodes (0.08mm diameter, 2mm uncoated
hook) were positioned for electrical stimulation near
the apex of the heart where BMMNC were trans-
planted. The distance between the two electrodes
was 2mm. To eliminate the eﬀect of changing heart
rate on VFT, VFT was determined by a train of pulse
after 60 paced beats at 400 bpm. A single train of 10
square wave stimuli (50Hz, pulse duration: 10msec)
was delivered over 200msec across the T wave
starting 10msec after the onset of the R wave. The
stimulation current was progressively increased in
100 mA steps starting at 100 mA until VF occurred.
VF was deﬁned as a minimum of six completely
irregular, continuous ectopic beats immediately
following the second train. The lowest current
(mA) inducing VF was taken as the VFT.
Measurement of MAP duration14) (n ¼ 5 for each
group)
MAPs were recorded at the apex, where BMMNC
was transplanted during constant pacing (cycle
length: from 150msec to 300msec). For recording
of the monophasic action potential (MAP), a
specially designed silver–silver chloride bipolar
contact electrode catheter (inter-electrode distance:
2mm) was inserted into the left ventricular cavity
through the aortic valve and positioned with its tip
electrode against the endocardium of the left
ventricle. The ECG, MAP and arterial pressure were
continuously recorded. The MAP signals were
ampliﬁed with a DC coupled diﬀerential ampliﬁer
(Iso-DAM8, WPI, Sarasota, USA) at a frequency
range from 0.1 to 1,000Hz. All data were digitized at
2,000Hz with the aid of a 12-bit resolution analog-
to-digital converter (AD12-16U(PCI)EH, Contec,
Osaka, Japan) hosted by a dedicated laboratory
computer system (PC Station, Sotec, Yokohama,
Japan). We measured MAP duration at 90% repola-
rization (MAPD90).
Statistical analysis
Data are presented as mean  standard error. The
diﬀerences of VTF or MAPD90 among groups were
analyzed using analysis of variance (ANOVA).
When the ANOVA showed signiﬁcant diﬀerence,
post-hoc test of Fisher PLSD was applied. Statistical
analysis was performed using the software package
Statview for Machintosh 5.0 (Abacus Concepts,
Berkeley, CA). Statistical signiﬁcance was set at
p < 0:05.
Results
Four weeks after cell transplantation, the mortality
rate of D–N group was 40%, and that of D–TX group
0
N-N D-TX D-N
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Figure 2 Ventricular ﬁbrillation threshold.
Individual data shows mean  standard error of ventricular
ﬁbrillation threshold (VFT). The doxorubicin signiﬁcantly de-
creased VFT in D–N and D–TX compared to N–N (p < 0:01).
On the other hand, the cell transplantation did not decrease VFT in
D–TX compared to that in D–N (p ¼ N.S.).
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was 31%. There was a trend toward an increased
mortality rate in D–N group, but it did not reach
statistical signiﬁcance.
VFT of the D–N was signiﬁcantly lower than that
of N–N (D–N: 2:2 0:6 vs. N–N: 5:7 1:0mA,
p < 0:01) (Figure 2). VFT of D–TX was comparable
to that of D–N and was signiﬁcantly lower than that
of N–N (D–TX: 2:4 0:7 vs. N–N: 5:7 1:0mA,
p < 0:01). VF induced by the train-stimuli method
spontaneously returned to sinus rhythm and the
duration of VF did not diﬀer among groups.
Regarding the distribution of values, the VFT ranged
from 1.5 to 12mA in N–N, from 0.4 to 7mA in D–
TX, and from 0.3 to 5mA in D–N.
Figure 3A shows representative MAP tracings
recorded from each groups. The length of the
MAPD90 at the apex resulted in the following order:
D–N > D–TX > N–N in all pacing cycles (Figure
3B). There were signiﬁcant diﬀerences between D–N
and N–N in the pacing cycles of 150, 200, and
250msec (p < 0:01), and between D–TX and N–N
in the pacing cycles of 150 and 200msec (p < 0:05).
There were no signiﬁcant diﬀerences between D–N
and D–TX in any pacing cycles.
Discussion
The goal of this study was to assess arrhythmo-
genic contribution of transplanted bone marrow cells
to the cardiomyopathic heart using a rat model. Our
ﬁndings indicate that the bone marrow cell trans-
plantation did not increase vulnerability to ventric-
ular arrhythmia in the measurement of VFT and
APD.
Several sources have shown the appropriate
application of two indexes, VFT and MAP duration,
for the research of arrhythmia in a rat model.15,16)
VFT is an experimental indicator of overall
ventricular vulnerability to ﬁbrillation. In our present
study, D–N showed signiﬁcantly lower VFT as
compared to N–N. This electrophysiological diﬀer-
ence suggests that doxorubicin toxicity clearly
inﬂuenced the rat heart and caused it to more easily
develop arrhythmia. On the other hand, D–TX
showed almost the same threshold level as D–N.
This ﬁnding suggested that the cardiomyopathic
heart to which bone marrow cells were transplanted
did not increase the vulnerability to arrhythmia in the
chronic phase (four weeks after cell transplantation).
There were some individual variations of VFT
data in each group in our study. As the VFT was
measured in vivo, the variability may result from
some factors: anesthetic agents, neurohumoral re-
ﬂexes, and cardiac performance during the test. To
exclude these variable factors, an isolated heart
model perfused through the Langendorﬀ apparatus is
one feasible alternative because of its electrical and
mechanical stability.17)
MAP recording is an essential part of electro-
physiological studies and gives us the precise
information on local myocardial repolarization and
activation. This information is useful to uncover the
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Figure 3 Monophasic action potential duration 90.
A. Representative monophasic action potential (MAP) tracings in each group. Solid line shows MAP recorded at a cycle length of
150msec, and dotted line shows it at 300msec.
B. Comparison of monophasic action potential duration90 (MAPD90) at the apex in all groups during steady-state pacing at diﬀerent
cycle lengths (D–N: — , D–TX: — , N–N:       ). Data are presented as mean  standard error. MAPD90 in D–N and
D–TX prolonged signiﬁcantly compared to N–N especially at fast pacing rates (as a cycle length of 150 to 200msec) (p < 0:01 vs.
N–N, yp < 0:05 vs. N–N). Cell transplantation did not increase the MAPD90 over the entire range of cycle lengths.
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mechanism of arrhythmia and to understand basic
electrophysiological principles.18) The prolongation
of APD produces early afterdepolarization which
plays an important role in inducing arrhythmia. At
the apex, MAPD90 of D–N was signiﬁcantly longer
than that of N–N. This result also indicates the
deleterious inﬂuence of doxorubicin as is shown in
the data of VFT. D–TX showed shorter MAPD90
compared to that of D–N, although it did not reach
statistical signiﬁcance. This result indicates that the
cell transplantation did not prolong APD and may
not accerelate repolarization abnormalities.
There are several limitations in this study. First, it
was not identiﬁed whether information derived from
small animal models would be applicable to larger
animals or humans. VF induced in small animals
spontaneously terminates. On the other hand, VF in
larger animals or human usually does not stop and
leads to death.19,20) Second, we performed the
electrophysiological studies only at one point,
namely at four weeks after the cell transplantation.
This time point does not necessarily represent the
timing of electrical instability of the myocardium
after the cell transplantation. We selected ‘‘four
weeks after the cell transplantation’’ in this study
because the surgical stress to the myocardium may
be minimal and does not inﬂuence the results of
electrophysiological testing in the chronic stage.
Third, we did not assess the relationship between the
electrophysiological data and the degree of cell
engraftment in the myocardium by the pathological
study. BMMNC was not labeled for identiﬁcation of
cell engraftment in this study because the labeling
procedure may deteriorate the cell function.21)
Fourth, we performed only one injection of BMMNC
into the rat heart. However, the patients actually
received multi-focal injection at the heart. Moreover,
multi-focal injection of BMMNC in the whole heart
may increase inequality of MAP duration and induce
arrhythmia more frequently compared to a single
injection. To investigate the inﬂuence of multi-focal
transplanted cells to arrhythmia before applying the
results of this study to the clinical situation, we need
to investigate the same study using larger animals,
such as pigs. Therefore, it may be important to
investigate a dose-response relationship, type of
cells, survival, and fate of transplanted cells related
to arrhythmogenicity, and to verify whether trans-
planted cells would indeed be proarrhythmic, espe-
cially using large animals.
Conclusion
In conclusion, the bone marrow cell transplanta-
tion did not increase vulnerability to arrhythmia
from the viewpoint of VFT and APD in a rat
doxorubicin-induced cardiomyopathy model.
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